Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam Besylate for Sedation in ICU Patients
NCT06124404Phase 2Completed
- Start
- Apr 2022
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, single-blind trial of remimazolam in sedation (3 arms). Primary endpoint: Percentage of time in the target sedation range without rescue sedation at 24 hours. Started Apr 2022; status: completed.
02
Drugs
remimazolam
03
Conditions
sedation
Beyond the preview
Go deeper on NCT06124404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06124404.